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Chapter 6
Childhood factors associated 
with complete and clinical 
asthma remission at 25 and 
49 years.
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To the editor:
Asthma may go into remission later in life in approximately 35% of asthma patients.1 The 
occurrence of asthma remission is associated with childhood onset of asthma2,3, male gender, 
quitting smoking, initially less severe airway obstruction and, intriguingly, more severe 
bronchial hyperresponsiveness (BHR).4,5 Unfortunately, subjects with asthma remission may 
show relapse later in life. There is sparse data available regarding childhood factors that 
predict clinical asthma remission in adulthood, and even less on complete asthma remission6 
or persistence of asthma remission throughout the lifespan. Therefore, the aim of the current 
study is to explore if asthma remission persists in children followed from childhood up to an 
average age of 49 years. Furthermore, we assessed which factors in childhood are associated 
with clinical and/or complete asthma remission that is retained during adulthood. 
An asthma cohort was created in 1972–1976 (visit 1) and re-investigated between 1987–
1989 (visit 2)7aged 8 to 12 years, was studied. Follow-up in adulthood was 86%, with a 
mean age of 24.7 years and a mean interval of follow-up of 14.8 years. The predictive value 
of gender and various childhood variables on the adult level of pulmonary function (forced 
expiratory volume in 1 second [FEV1] and 2013-2014 (visit 3). At visit 1, 406 children, 
diagnosed with asthma were referred to the University Medical Center Groningen, and 
characterised by extensive standardized questionnaires, peripheral blood measurements, 
BHR, lung function and skin prick tests. At visit 2, 285 children (209 children with BHR at visit 
1) were re-examined in young adulthood. At visit 3, 102 subjects with BHR at visit 1 were 
included and re-examined.
The presence of persistent asthma (PersA), clinical asthma remission (ClinR) and complete 
asthma remission (ComR) was determined at visits 2 and 3. ClinR was defined as the absence 
of symptoms (dyspnea attacks and/or wheeze) and no asthma medication in the last year, 
irrespective of the presence or absence of a positive BHR test (visit 2: PC10 histamine ≤16 
mg/ml, visit 3: PC20 methacholine ≤39.3mg/ml) and/or normal FEV1 (>80% of predicted pre-
bronchodilator). ComR was defined as ClinR, combined with a negative BHR test and a normal 
FEV1 (>80% of predicted pre-bronchodilator) (Supplemental Figure 1). PersA subjects still 
had symptoms and/or used asthma medication. Associations between childhood factors and 
asthma outcome (ComR vs. PersA and ComR/ClinR vs. PersA) at visits 2 and 3 were studied by 
performing multivariate logistic regression with adjustment for sex and age at visit 1 using 
SPSS 22 (SPSS Inc, Chicago, IL). A p-value <0.05 was considered statistically significant.
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Of the initial cohort of 406 children, 209 had BHR at visit 1. At visit 2, 188 subjects were re-
assessed at a mean age of 25 (±2) years, of whom 25 subjects only completed questionnaires. 
At visit 3, 102 subjects with a mean age of 49 (±2) years were re-assessed, of whom 34 
subjects only completed questionnaires (Supplemental figure 2).
Subjects who only completed questionnaires at visit 2 or 3 could only be classified as 
ClinR or PersA, since BHR and FEV1 were missing. Subjects with only questionnaire data at 
visit 2 had significantly lower FEV1/FVC values at baseline compared to subjects with both 
questionnaire and spirometry data, without any other statistically significant demographic 
differences (Supplemental Table 1).
The prevalence of complete remission was 7% at age 25 and 10% at age 49, indicating that 
ComR is a rare phenomenon. Only one other study used the same definition and reported 
that 22% of asthmatic children were in ComR after a follow-up from 10 to 38 years.8 The 
prevalence of ComR in our study is probably an underestimation since information on BHR 
and FEV1 was missing in almost half of the ClinR subjects.
Sixty-three subjects were fully examined during both follow-up visits (Supplemental figure 
3). Of all subjects with PersA at visit 2, 15 developed ClinR (29%) and 4 developed ComR 
(8%) at visit 3. Sevenof all 63 subjects (11%) had ComR/ClinR at age 25 through age 49. The 
prevalence of asthma-relapse at visit 3 was 36%, i.e. clinical asthma after ComR/ClinR at visit 
2).Of importance, using the strict remission definition, 75% of the subjects with ComR at age 
25 had no relapse of asthma by the age of 49. 
Table 1 shows results of the analyses on childhood factors associated with ComR vs. PersA 
and ComR/ClinR vs. PersA. Presented variables are childhood factors associated with asthma 
remission in previous studies2,4,5,8-10 and statistically significant factors in the present study 
(Supplemental Tables 3-6 for complete results). Three childhood factors were positively 
associated with ComR at visit 2, i.e. leukaemia in the family, a higher FEV1/IVC ratio and a 
positive SPT for mould. Acute lymphocytic leukaemia has been previously associated with 
a lower prevalence of atopic diseases.11,12 This inverse relationship may be caused by an 
imbalance of Th1 and Th2 cells, predisposing to either autoimmune or atopic disease.13 
Although only 5 children had a family history for leukaemia in our cohort, results suggest that 
this phenomenon also may play a role in asthma remission. 
Two childhood factors that reduced the chance of ComR at visit 2 are symptoms of wheeze 
and an atopic mother. The finding that children of an atopic mother have less frequently 
ComR or ClinR at 25 years, is in accordance with Burgess et al. who found less ClinR in these 
subjects.3 
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Table 1: Childhood factors associated with Complete and Clinical asthma remission 
 
Complete remission vs.  
Persistent Asthma 
Complete/Clinical remission vs. 
Persistent asthma 
  
Visit 2: 25 years 
Rem (n= 14) 
Asthma (n=154) 
Visit 3: 49 years 
Rem (n=10) 
Asthma (n=61) 
 Visit 2: 25 years 
Rem (n=34)  
Asthma (n=154) 
Visit 3: 49 years  
Rem (n=41)  
Asthma (n=61) 
 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Characteristics         
Age at 1st visit, years 1.3 (0.9-1.9) 1.0 (0.6-1.5) 1.0 (0.8-1.3) 1.0 (0.7-1.3) 
Period between visits, years 1.3 (0.9-1.9) 1.0 (0.9-1.1) 1.1 (0.9-1.4) 1.0 (0.9-1.1) 
Male sex 1.7 (0.4-6.3) 1.4 (0.3-6.0) 2.7 (.99-7.4) 1.9 (0.8-4.5) 
Symptoms         
Sputum 0.6 (0.2-2.0) 0.4 (0.1-1.7) 0.8  (0.4-1.8) 0.4 (0.1-0.8) 
Shortness of breath at rest 0.7 (0.2-2.5) 0.4 (0.1-2.3) 1.1 (0.5-2.6) 0.3 (0.1-0.9) 
Attack of dyspnea at rest with wheezing 0.5 (0.2-1.8) 0.4 (0.1-2.0) 1.0 (0.4-2.6) 0.5 (0.2-1.2) 
Wheeze during a cold 0.2 (0.1-0.7) 6.3 (0.7-56.4) 0.2 (0.1-0.7) 2.0 (0.8-5.0) 
Cough 1.8 (0.4-8.6) 0.9 (0.2-4.7) 0.8 (0.3-1.8) 0.8 (0.3-2.4) 
Peripheral blood measurements         
Ln eosinophil count, x 106/L 0.9 (0.5-1.5) 1.0 (0.6-1.9) 0.8 (0.6-1.2) 1.2 (0.8-1.9) 
Total protein <25th percentile (<6.8 g/dL) 0.2 (0.03-1.8) 1.8 (0.4-8.2) 0.2 (0.1-0.8) 1.4 (0.5-3.8) 
Peri- and postnatal factors         
Breastfeeding > 6 months 2.4 (0.2-28.1) 1.0* 5.5 (1.1-27.1) 0.3 (0.1-2.1) 
History of pneumonia 0.2 (0.03-1.8) 0.5 (0.1-4.8) 0.1 (0.01-0.9) 0.7 (0.2-2.2) 
Environmental exposures         
Pets in household 1.3 (0.4-4.1) 2.4 (0.4-12.5) 1.1 (0.5-2.5) 3.1 (1.2-8.2) 
Firstborn child 1.5 (0.4-4.4) 0.5 (0.1-2.7) 0.7 (0.3-1.6) 0.9 (0.3-2.1) 
House dusty/damp/rotten floors/mouldy a 2.9 (0.8-11.0) 1.7 (0.3-11.6) 3.1 (1.2-8.2) 1.6 (0.5-4.6) 
Family history         
Atopic father 0.9 (0.2-3.6) 0.5 (0.1-3.0) 1.4 (0.6-3.5) 0.6 (0.2-1.5) 
Atopic mother 0.02* 0.18* 0.1 (0.01-0.7) 0.3 (0.1-1.1) 
Cardiac disease in the family 3.2 (0.9-10.9) 2.0 (0.3-11.5) 2.8 (1.1-6.8) 2.0 (0.6-6.2) 
Leukaemia in the family 18.0 (2.6-124) 1.0 * 7.6 (1.2-49.0) 1.2 (0.2-9.2) 
Lung function         
FEV1 % predicted 1.0 (0.99-1.1) 1.0 (0.96-1.1) 1.0 (0.99-1.1) 1.0 (0.97-1.1) 
FEV1 % predicted <80 0.4 (0.1-1.1) 0.8 (0.2-3.2) 0.5 (0.2-0.97) 1.4 (0.6-3.2) 
FEV1 % IVC ratio 1.1 (1.01-1.2) 1.1 (0.97-1.2) 1.0 (0.97-1.1) 1.0 (0.96-1.1) 
FEF25-75% IVC ratio 1.0 (0.99-1.05) 1.0 (0.99-1.1) 1.0 (0.99-1.03) 1.0 (0.99-1.03) 
Skin prick test         
House dust mite positive# 0.7 (0.2-2.4) 3.3 (0.8-14.2) 0.7 (0.3-1.6) 1.0 (0.4-2.2) 
Mould positive# 8.8 (1.7-46.1) 9.4 (0.99-89.5) 3.6 (0.9-14.1) 3.1 (0.5-18.7) 
Any skin prick test positive# 0.8 (0.2-2.3) 2.5 (0.6-11.0) 0.9 (0.4-1.9) 0.8 (0.3-1.8) 
Hyperresponsiveness         
2log(Histamine threshold), mg/ml 1.1 (0.7-1.6) 1.9 (0.8-4.7) 1.0 (0.8-1.3) 0.9 (0.6-1.2) 
Histamine threshold, mg/ml 0.8 (0.2-2.8) 0.11* 1.1 (0.5-2.6) 1.5 (0.6-3.6) 
Data are presented as mean (SD), median (25th-75th percentile), or n (%). Rem: remission; n=number OR: odd ratio of the 
childhood factor, corrected for sex and age at visit 1 with 95% Confidence Interval, a: characteristics of house include ≥1 of the 
following: dusty/moisty vs. dry house, rotten floor and/or mould in house  
* p-value Fisher’s exact test 
# times higher than the diameter of the positive histamine control 
Table 1: Childhood factors associated with Complete and Clinical asthma remission
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Table 1: Childhood factors associated with Complete and Clinical asthma remission 
 
Complete remission vs.  
Persistent Asthma 
Complete/Clinical remission vs. 
Persistent asthma 
  
Visit 2: 25 years 
Rem (n= 14) 
Asthma (n=154) 
Visit 3: 49 years 
Rem (n=10) 
Asthma (n=61) 
 Visit 2: 25 years 
Rem (n=34)  
Asthma (n=154) 
Visit 3: 49 years  
Rem (n=41)  
Asthma (n=61) 
 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Characteristics         
Age at 1st visit, years 1.3 (0.9-1.9) 1.0 (0.6-1.5) 1.0 (0.8-1.3) 1.0 (0.7-1.3) 
Period between visits, years 1.3 (0.9-1.9) 1.0 (0.9-1.1) 1.1 (0.9-1.4) 1.0 (0.9-1.1) 
Male sex 1.7 (0.4-6.3) 1.4 (0.3-6.0) 2.7 (.99-7.4) 1.9 (0.8-4.5) 
Symptoms         
Sputum 0.6 (0.2-2.0) 0.4 (0.1-1.7) 0.8  (0.4-1.8) 0.4 (0.1-0.8) 
Shortness of breath at rest 0.7 (0.2-2.5) 0.4 (0.1-2.3) 1.1 (0.5-2.6) 0.3 (0.1-0.9) 
Attack of dyspnea at rest with wheezing 0.5 (0.2-1.8) 0.4 (0.1-2.0) 1.0 (0.4-2.6) 0.5 (0.2-1.2) 
Wheeze during a cold 0.2 (0.1-0.7) 6.3 (0.7-56.4) 0.2 (0.1-0.7) 2.0 (0.8-5.0) 
Cough 1.8 (0.4-8.6) 0.9 (0.2-4.7) 0.8 (0.3-1.8) 0.8 (0.3-2.4) 
Peripheral blood measurements         
Ln eosinophil count, x 106/L 0.9 (0.5-1.5) 1.0 (0.6-1.9) 0.8 (0.6-1.2) 1.2 (0.8-1.9) 
Total protein <25th percentile (<6.8 g/dL) 0.2 (0.03-1.8) 1.8 (0.4-8.2) 0.2 (0.1-0.8) 1.4 (0.5-3.8) 
Peri- and postnatal factors         
Breastfeeding > 6 months 2.4 (0.2-28.1) 1.0* 5.5 (1.1-27.1) 0.3 (0.1-2.1) 
History of pneumonia 0.2 (0.03-1.8) 0.5 (0.1-4.8) 0.1 (0.01-0.9) 0.7 (0.2-2.2) 
Environmental exposures         
Pets in household 1.3 (0.4-4.1) 2.4 (0.4-12.5) 1.1 (0.5-2.5) 3.1 (1.2-8.2) 
Firstborn child 1.5 (0.4-4.4) 0.5 (0.1-2.7) 0.7 (0.3-1.6) 0.9 (0.3-2.1) 
House dusty/damp/rotten floors/mouldy a 2.9 (0.8-11.0) 1.7 (0.3-11.6) 3.1 (1.2-8.2) 1.6 (0.5-4.6) 
Family history         
Atopic father 0.9 (0.2-3.6) 0.5 (0.1-3.0) 1.4 (0.6-3.5) 0.6 (0.2-1.5) 
Atopic mother 0.02* 0.18* 0.1 (0.01-0.7) 0.3 (0.1-1.1) 
Cardiac disease in the family 3.2 (0.9-10.9) 2.0 (0.3-11.5) 2.8 (1.1-6.8) 2.0 (0.6-6.2) 
Leukaemia in the family 18.0 (2.6-124) 1.0 * 7.6 (1.2-49.0) 1.2 (0.2-9.2) 
Lung function         
FEV1 % predicted 1.0 (0.99-1.1) 1.0 (0.96-1.1) 1.0 (0.99-1.1) 1.0 (0.97-1.1) 
FEV1 % predicted <80 0.4 (0.1-1.1) 0.8 (0.2-3.2) 0.5 (0.2-0.97) 1.4 (0.6-3.2) 
FEV1 % IVC ratio 1.1 (1.01-1.2) 1.1 (0.97-1.2) 1.0 (0.97-1.1) 1.0 (0.96-1.1) 
FEF25-75% IVC ratio 1.0 (0.99-1.05) 1.0 (0.99-1.1) 1.0 (0.99-1.03) 1.0 (0.99-1.03) 
Skin prick test         
House dust mite positive# 0.7 (0.2-2.4) 3.3 (0.8-14.2) 0.7 (0.3-1.6) 1.0 (0.4-2.2) 
Mould positive# 8.8 (1.7-46.1) 9.4 (0.99-89.5) 3.6 (0.9-14.1) 3.1 (0.5-18.7) 
Any skin prick test positive# 0.8 (0.2-2.3) 2.5 (0.6-11.0) 0.9 (0.4-1.9) 0.8 (0.3-1.8) 
Hyperresponsiveness         
2log(Histamine threshold), mg/ml 1.1 (0.7-1.6) 1.9 (0.8-4.7) 1.0 (0.8-1.3) 0.9 (0.6-1.2) 
Histamine threshold, mg/ml 0.8 (0.2-2.8) 0.11* 1.1 (0.5-2.6) 1.5 (0.6-3.6) 
Data are presented as mean (SD), median (25th-75th percentile), or n (%). Rem: remission; n=number OR: odd ratio of the 
childhood factor, corrected for sex and age at visit 1 with 95% Confidence Interval, a: characteristics of house include ≥1 of the 
following: dusty/moisty vs. dry house, rotten floor and/or mould in house  
* p-value Fisher’s exact test 
# times higher than the diameter of the positive histamine control 
Four childhood factors increased the chance of ComR/ClinR at visit 2: being breastfed for 
more than 6 months, living in a dusty/damp house, with rotten floors and/or mould, a family 
member with cardiac disease, or with leukaemia. At visit 3, having pets in childhood was 
positively associated with ComR/ClinR. Additionally, being breastfed for more than six 
months was associated with ComR/ClinR. A systematic review reported a reduced asthma 
risk in breastfed children.14 Furthermore, breastfed children are less susceptible to early 
life respiratory infections, which is associated with asthma development and persistence.15 
Further studies need to assess whether prolonged breastfeeding is also able to provide an 
opportunity to develop asthma remission when asthma has developed. 
There were five factors that reduced the chance of ComR/ClinR at visit 2, i.e. symptoms 
of wheeze during a cold, total protein level <25th percentile, pneumonia in childhood, an 
atopic mother and FEV1<80% of predicted. At visit 3, sputum production in childhood was 
negatively associated with ComR/ClinR (table 1). Children of an atopic mother had less 
frequently ComR/ClinR and ComR at 25 years, while there was no association with atopy in 
the father. This finding is in accordance with another study that also found less ComR/ClinR 
in children of a mother with asthma.3 
In conclusion, our study shows that it is truly possible to have persistent asthma remission 
after childhood asthma over 39 years of follow-up, yet this only occurred in 11% of the 
asthmatics we studied. Importantly, using the strict definition of complete asthma remission, 
we show that when complete remission is present at age 25, 75% of this group has persistent 
remission to age 49. Several factors in childhood were found to be associated with a higher 
chance of asthma remission in adulthood, e.g. breastfeeding >6 months and leukemia in the 
family, or a lower chance of asthma remission, e.g. wheeze during a cold in childhood and an 
atopic mother. However, more research is needed to confirm our observations, using larger 
cohorts with uniform definition of asthma remission.
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Spirometry measurements
Predicted spirometry values at all visits were those of Quanjer (2012). At visit 1 and 2, 
the histamine concentration (range 0.5 to 32 mg/ml) with a decrease in FEV1 >10% from 
pre-challenge FEV1 was taken as the threshold for BHR. At visit 3, the BHR-test was discontinued 
if the FEV1 decreased ≥20% from pre-challenge FEV1 or if the highest dose of methacholine 
bromide (range 0.038 – 39.3 mg/ml) had been given. The skin prick test (SPT) was regarded 
positive if the mean of the perpendicular diameters of the wheal was > 0.7 times the mean 
diameter of histamine as positive control.
Supplemental Figure 1: Flow chart to define persistent asthma, clinical asthma remission and 
complete asthma remission





Supplemental Figure 2: Subject recruitment
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Supplemental Figure 2: Subject recruitment
Supplemental Figure 3: Course of asthma status
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Supplemental Figure 3: Course of asthma status 
  

































































































































































































































































































































































































































































































































































































































































OR (95% CI) P
Characteristics
Age at first visit, years 10.1 (1.2) 9.6 (1.5) 168 1.3 (0.9-1.9) .20





168 1.3 (0.9-1.9) .18
Male seks 11 (78.6) 105 (68.5) 168 1.7 (0.4-6.3) .45
Weight at first visit, kg 34.7 (6.3) 32.8 (6.7) 166 1.0 (0.9-1.1) .84
Height at first visit, cm 146.6 (10.1) 142.8 (9.6) 168 1.0 (0.9-1.1) .56
Cough 12 (85.7) 118 (77.6) 166 1.8 (0.4-8.6) .46
Age at development of cough, years 2 (0-4) 4 (1-6) 124 0.9 (0.7-1.1) .20
Cough accompanied by fever 5 (38.5) 55 (41.0) 147 0.9 (0.3-3.1) .93
Cough ≥ 3 months 2 (16.7) 52 (40.3) 141 0.3 (0.1-1.6) .16
Sputum 5 (38.5) 71 (48.0) 161 0.6 (0.2-2.0) .41
Shortness of breath at rest 3 (21.4) 42 (29.4) 157 0.7 (0.2-2.5) .53
Shortness of breath during walking 
stairs/playing
2 (14.3) 34 (25.8) 146 0.5 (0.1-2.2) .33
Shortness of breath during cycling 
against the wind
8 (57.1) 109 (75.2) 159 0.4 (0.1-1.3) .13
Age at development of shortness of 
breath, years
5 (1-8) 4 (1-7) 112 1.0 (0.8-1.2) .85
Attack of dyspnea at rest with 
wheezing
10 (71.4) 125 (82.8) 165 0.5 (0.2-1.8) .31
Wheeze ever 10 (76.9) 132 (93.0) 155 0.3 (0.1-1.1) .07
Wheeze during a cold 4 (30.8) 82 (66.1) 137 0.2 (0.1-0.8) .02
Wheeze without a cold 4 (30.8) 51 (43.6) 130 0.5 (0.2-1.9) .32
Runny or stuffed nose 10 (71.4) 84 (58.3) 158 1.7 (0.5-5.8) .39
Age at development of runny/stuffed 
nose, years
5 (2-9) 4 (2-7) 86 1.0 (0.8-1.2) .68
Eczema 6 (42.9) 65 (43.9) 162 1.0 (0.3-3.1) .98
Urticaria 2 (14.3) 14 (10.2) 151 1.4 (0.3-6.9) .71
≥3 symptoms: cough, sputum, 
shortness of breath  
at rest, attack of dyspnea at rest with 
wheezing, wheeze ever
9 (75.0) 100 (75.2) 145 1.0 (0.2-3.8) .97
Physical signs of pulmonary rhonchi 4 (40.0) 64 (64.0) 110 0.4 (0.1-1.5) .16
Physical signs of thorax deformation 4 (40.0) 22 (22.0) 110 1.5 (0.4-6.4) .56
Supplemental table 2: complete list of childhood factors ComR versus PersA at visit 2








OR (95% CI) P
Peripheral blood measurements
LN Leukocyte count, cells x 106/L 8.9 (0.2) 9.0 (0.3) 164 0.6 (0.1-5.4) .67
Leukocyte count level 75th percentile 
(>9.600 x 106/L )
4 (28.6) 38 (25.3) 164 1.2 (0.4-4.2) .73
Leukocyte count level 90th percentile 
(>10.880 x 106/L)
0 (0.0) 14 (9.3) 164 Fisher’s .61
Haemoglobin, g/dL 13.2 (1.0) 13.6 (1.0) 163 0.6 (0.4-1.2) .16
Haemoglobin level 75th percentile 
(>14.2g/dL)
3 (21.4) 33 (22.1) 163 0.9 (0.2-3.4) .87
Haemoglobin level 90th percentile 
(>14.8g/dL)
0 (0.0) 13 (8.7) 163 Fisher’s .61
LN eosinophil count, cells x 106/L 5.8 (0.8) 5.9 (1.0) 164 0.9 (0.5-1.5) .69
Eosinophil count level 75th percentile 
(>699 106/L )
3 (21.4) 40 (26.7) 164 0.8 (0.2-3.0) .74
Eosinophil count level 90th percentile 
(>961 106/L)
2 (14.3) 12 (8.0) 164 2.3 (0.4-11.9) .32
Electrophoresis total protein, g/dL 7.1 (6.9-7.5) 7.0 (6.7-7.4) 165 1.1 (0.6-2.2) .74
Total protein level 25th percentile 
(<6.8g/dL)
1 (7.1) 42 (27.8) 165 0.2 (0.03-1.8) .16
Total protein level 10th percentile 
(<6.5g/dL)
0 (0.0) 19 (12.6) 165 Fisher’s .37
Electrophoresis albumin, % of total 
protein
61.6 (10.4) 65.2 (7.8) 168 0.9 (0.9-1.01) .10
Albumin level 25th percentile (<60.2g/dL) 4 (28.6) 40 (26.0) 168 1.2 (0.3-4.3) .76
Albumin level 10th percentile (<55.6g/dL ) 3 (21.4) 16 (10.4) 168 2.8 (0.7-11.7) .17















148 0.9 (0.6-1.3) .59
Premature birth (≤37 weeks) 0 (0.0) 5 (3.7) 148 Fisher’s 1.0
Use of caesarean section at birth 0 (0.0) 5 (5.4) 101 Fisher’s 1.0
Use of forceps at birth 1 (10.0) 3 (3.3) 101 3.6 (0.3-43.9) .31
Birth weight, kg 4.0 (3.4-4.0) 3.5 (3.2-4.0) 110 1.2 (0.5-3.0) .75
Weight <2.5 kg at birth 0 (0.0) 4 (4.0) 110 Fisher’s 1.0
Hospital childbirth 4 (30.8) 28 (21.5) 143 1.5 (0.4-5.3) .53
Cyanosis at birth 1 (7.7) 15 (10.6) 155 0.5 (0.1-4.7) .58
Shortness of breath at birth 0 (0.0) 7 (4.9) 156 Fisher’s 1.0
Icterus at birth 2 (14.3) 19 (13.2) 158 1.2 (0.2-6.1) .80
Duration of breastfeeding, months 4.0 (0.9-7.5) 3.0 (1.5-6.0) 62 1.1 (0.7-1.6) .67
Duration of breastfeeding  >6 months 1 (20.0) 7 (12.3) 62 2.4 (0.2-28.1) .50
History of variola vaccination 7 (63.6) 103 (72.0) 154 0.7 (0.2-2.7) .63
History of DKTP vaccination 13 (100.0) 146 (98.6) 161 Fisher’s 1.0
History of morbili vaccination 1 (11.1) 12 (10.4) 124 1.1 (0.1-9.6) .94
History of otitis 5 (35.7) 43 (29.3) 161 1.4 (0.4-4.3) .60
History of pseudo croup 0 (0.0) 15 (11.0) 150 Fisher’s .36
History of surgery for acute tonsillitis 9 (64.3) 97 (64.3) 167 1.1 (0.3-3.3) .93
Age at surgery for acute tonsillitis, 
years
5 (2-6) 4 (4-5) 94 0.9 (0.6-1.3) .51
History of pneumonia 1 (7.7) 30 (23.3) 142 0.2 (0.03-1.8) .16
History of scarlet fever 1 (7.1) 11 (7.3) 164 0.9 (0.1-7.4) .89
History of morbili 11 (78.6) 127 (84.7) 164 0.7 (0.2-2.8) .61
History of rubella 4 (30.8) 72 (50.0) 157 0.5 (0.1-1.6) .22
History of varicella 9 (64.3) 110 (72.8) 165 0.6 (0.2-2.1) .46
History of smallpox 0 (0.0) 1 (0.7) 156 Fisher’s 1.0
History of parotitis epidemica 8 (61.5) 86 (57.7) 162 1.2 (0.4-3.8) .79
≥1 of scarlet fever, morbili, rubella, 
varicella, smallpox, parotitis 
epidemica
13 (92.9) 147 (97.4) 165 0.3 (0.03-3.3) .33
≥1 of scarlet fever, rubella, varicella, 
smallpox, parotitis epidemica
12 (85.7) 137 (91.9) 163 0.5 (0.1-2.8) .47








OR (95% CI) P
Exposure
Contact with animals 2 (15.4) 43 (31.9) 148 0.4 (0.1-1.9) .25
Pets 9 (64.3) 87 (58.8) 162 1.3 (0.4-4.1) .65
Firstborn child 7 (50.0) 56 (38.4) 160 1.5 (0.5-4.4) .52
Rented house 4 (28.6) 68 (54.0) 140 0.3 (0.1-1.2) .09
Dusty or damp vs. dry house 0 (0.0) 10 (8.1) 135 Fisher’s 1.0
Rotten floor in house 2 (14.3) 4 (3.1) 144 5.3 (0.8-33.6) .08
Mould in house 2 (14.3) 7 (5.4) 143 3.0 (0.5-17.0) .21
≥1 of dusty/damp house, rotten floor, 
mould in house 4 (33.3) 16 (13.9 127 2.9 (0.8-11.0) .12
Old state of house 2 (15.4) 54 (40.6) 146 0.2 (0.04-1.04) .06
Kapok/feather mattress 2 (15.4) 12 (8.3) 158 2.4 (0.4-12.8) .31
Kapok/feather pillow 5 (41.7) 41 (29.3) 152 1.8 (0.5-6.2) .34
Use of gas heater 8 (57.1) 69 (52.7) 145 1.1 (0.3-3.4) .92
Family history
Age of father, years 39 (35-45) 40 (36-44) 146 1.0 (0.9-1.1) .79
Age father at birth of child, years 29 (26-34) 30 (27-34) 146 1.0 (0.9-1.1) .79
Age of mother, years 36 (34-45) 37 (34-42) 147 1.0 (0.9-1.1) .99
Age mother at birth of child, years 27 (23-34) 27 (25-32) 147 1.0 (0.9-1.1) .99
Father with asthma 2 (15.4) 17 (12.5) 149 1.6 (0.3-8.3) .57
Father with bronchitis 2 (15.4) 24 (18.0) 146 1.0 (0.2-4.8) .97
Father with eczema 1 (7.7) 15 (11.4) 145 0.8 (0.1-6.5) .81
Father with hayfever 1 (7.7) 13 (9.8) 146 0.9 (0.1-8.5) .96
Father with atopic symptoms (asthma, 
eczema, hay fever) 3 (23.1) 38 (27.9) 149 0.9 (0.2-3.6) .88
Mother with asthma 0 (0.0) 17 (12.6) 148 Fisher’s .36
Mother with bronchitis 1 (7.7) 25 (18.7) 147 0.4 (0.05-3.0) .35
Mother with eczema 0 (0.0) 15 (11.3) 146 Fisher’s .36
Mother with hayfever 0 (0.0) 12 (9.0) 146 Fisher’s .60
Mother with atopic symptoms 
(asthma, eczema, hay fever) 0 (0.0) 39 (28.9) 148 Fisher’s .02
Rest of the family with asthma 8 (61.5) 67 (48.6) 151 1.8 (0.5-5.7) .35
Rest of the family with bronchitis 5 (41.7) 69 (51.5) 146 0.7 (0.2-2.3) .52
Rest of the family with eczema 4 (33.3) 43 (32.8) 143 1.2 (0.3-4.4) .77
Rest of the family with hay fever 1 (7.7) 18 (14.0) 142 0.6 (0.1-5.0) .63
Family with atopic symptoms (asthma, 
eczema, hay fever) 11 (84.6) 91 (66.4) 150 3.3 (0.7-16.1) .14
Family members with rheumatoid 
arthritis 1 (7.7) 24 (17.6) 149 0.4 (0.04-2.9) .34
Family members with heart disease 5 (38.6) 21 (15.6) 148 3.2 (0.9-10.9) .06
Family members with mental retardation 0 (0.0) 8 (5.9) 148 Fisher’s 1.0
Family members with diabetes mellitus 5 (38.5) 39 (28.5) 150 1.8 (0.5-6.2) .33
Family members with leukaemia 3 (23.1) 2 (1.5) 149 18.0 (2.6-124) .003















168 1.0 (0.99-1.1) .08
FEV1 % predicted < 80 6 (42.9) 102 (66.2) 168 0.4 (0.1-1.1) .07
FEV1 % predicted <70 3 (21.4) 47 (30.5) 168 0.6 (0.2-2.3) .46






168 1.1 (1.01-1.2) .02
FEV1%IVC < 70 3 (21.4) 52 (33.8) 168 0.5 (0.1-1.8) .28




FEF25-75%IVC < 70 4 (30.8) 57 (47.5) 133 0.5 (0.1-1.6) .23
FEF25-75%IVC < 50 1 (7.7) 24 (20.0) 133 0.3 (0.04-2.6) .28
RV%TLC 21.9 (7.4) 21.3 (6.8) 167 1.0 (0.9-1.1) .80
Skin prick test (histamine-adjusted)
House dust mite positive 5 (35.7) 66 (45.5) 159 0.7 (0.2-2.4) .62
Hairs and feathers positive 5 (35.7) 42 (29.4) 157 1.4 (0.4-4.6) .54
Moulds positive 3 (23.1) 8 (5.6) 156 8.8 (1.7-46.1) .01
Grass pollen positive 4 (28.6) 24 (16.8) 157 2.1 (0.6-7.5) .26
Any SPT positive 6 (42.9) 74 (51.4) 158 0.8 (0.2-2.3) .63
BHR provocation test
2log (Histamine threshold), mg/ml 4 (3-4) 3 (2-4) 168 1.1 (0.7-1.6) .80
Histamine threshold < 8 mg/ml 6 (42.9) 79 (51.3) 168 0.6 (0.2-2.0) .43
Histamine threshold < 4 mg/ml 3 (21.4) 42 (27.3) 168 0.7 (0.2-2.8) .67
Data are presented as mean (SD), median (25th-75th percentile), or n (%). Odds Ratios (OR) with 95% 
Confidence Intervals (CI) are given for a logistic regression model adjusted for age at visit 1 and sex. 
If one of the groups contains 0 cases the p-value for the Fisher’s exact test is given. 









OR (95% CI) P
Characteristics
Age at first visit, years 9.6 (1.3) 9.6 (1.5) 188 1.0 (0.8-1.3) .99





188 1.1 (0.9-1.4) .40
Male sex 29 (85.3) 105 (68.3) 188 2.7 (0.99-7.4) .05
Weight at first visit, kg 32.7 (5.6) 32.8 (6.7) 186 1.0 (0.9-1.1) .70
Height at first visit, cm 143.2 (9.5) 142.8 (9.6) 188 1.0 (0.9-1.1) .94
Cough 25 (73.5) 118 (77.6) 186 0.8 (0.3-1.8) .53
Age at development of cough, years 2 (0-5) 4 (1-6) 138 0.9 (0.8-1.05) .19
Cough accompanied by fever 12 (37.5) 55 (41.0) 166 0.9 (0.4-1.9) .73
Cough ≥ 3 months 8 (26.7) 52 (40.3) 159 0.5 (0.2-1.3) .15
Sputum 14 (43.8) 71 (48.0) 180 0.8 (0.4-1.8) .65
Shortness of breath at rest 10 (31.3) 42 (29.4) 175 1.1 (0.5-2.6) .79
Shortness of breath during walking 
stairs/playing
8 (25.8) 34 (25.8) 163 0.9 (0.4-2.3) .84
Shortness of breath during cycling 
against the wind
22 (64.7) 109 (75.2) 179 0.5 (0.2-1.2) .15
Age at development of shortness of 
breath, years
6 (2-8) 4 (1-7) 125 1.1 (0.9-1.3) .25
Attack of dyspnea at rest with 
wheezing
28 (82.4) 125 (82.8) 185 1.0 (0.4-2.6) .96
Wheeze ever 29 (87.9) 132 (93.0) 175 0.6 (0.2-2.0) .38
Wheeze during a cold 11 (36.7) 82 (66.1) 154 0.3 (0.1-0.7) .004
Wheeze without a cold 12 (41.4) 51 (43.6) 146 0.9 (0.4-2.0) .76
Runny or stuffed nose 23 (69.7) 84 (58.3) 177 1.7 (0.8-4.0) .19
Age at development of runny/stuffed 
nose, years
6 (2-8) 4 (2-8) 93 1.0 (0.9-1.2) .80
Eczema 17 (50.0) 65 (43.9) 182 1.4 (0.6-2.9) .42
Urticaria 3 (9.7) 14 (10.2) 168 1.0 (0.3-3.9) .99
≥3 symptoms: cough, sputum, 
shortness of breath at rest, attack 
of dyspnea at rest with wheezing, 
wheeze ever
23 (79.3) 100 (75.2) 162 1.3 (0.5-3.4) .65
Physical signs of pulmonary rhonchi 10 (45.5) 64 (64.0) 122 0.4 (0.1-1.1) .07
Physical signs of thorax deformation 7 (31.8) 22 (22.0) 122 1.3 (0.4-3.8) .64
Supplemental table 3: All investigated childhood factors for ComR/ClinR versus PersA at visit 2








OR (95% CI) P
Peripheral blood measurements
LN Leukocyte count, cells x 106/L 9.0 (0.2) 9.0 (0.3) 184 1.1 (0.2-4.7) .93
Leukocyte count level 75th percentile 
(>9.600 x106/L)
8 (23.5) 38 (25.3) 184 0.9 (0.4-2.2) .86
Leukocyte count level 90th percentile 
(>10.880 106/L)
1 (2.9) 14 (9.3) 184 0.3 (0.04-2.4) .26
Haemoglobin, g/dL 13.6 (1.2) 13.6 (1.0) 182 1.0 (0.7-1.5) .92
Haemoglobin level 75th percentile 
(>14.2 g/dL)
9 (27.3) 33 (22.1) 182 1.3 (0.5-3.1) .58
Haemoglobin level 90th percentile 
(>14.8 g/dL)
4 (12.1) 13 (8.7) 182 1.6 (0.5-5.4) .47
LN eosinophil count, cells x 106/L 5.8 (0.9) 5.9 (1.0) 184 0.8 (0.6-1.2) .36
Eosinophil count level 75th percentile 
(>699 x 106/L)
5 (14.7) 40 (26.7) 184 0.5 (0.2-1.4) .19
Eosinophil count level 90th percentile 
(>961 x 106/L)
4 (11.8) 12 (8.0) 184 1.7 (0.5-5.8) .40
Electrophoresis total protein, g/dL 7.1 (7.0-7.4) 7.0 (6.7-7.4) 184 1.1 (0.7-1.9) .64
Total protein level 25th percentile  
(<6.8 g/dL)
3 (9.1) 42 (27.8) 184 0.2 (0.1-0.8) .03
Total protein level 10th percentile  
(<6.5 g/dL)
0 (0.0) 19 (12.6) 184 Fisher’s .03
Electrophoresis albumin, % of total 
protein
64.0 (8.2) 65.2 (7.8) 188 1.0 (0.9-1.02) .24
Albumin level 25th percentile  
(<60.2g/dL)
9 (26.5) 40 (26.0) 188 1.3 (0.5-3.0) .61
Albumin level 10th percentile  
(<55.6g/dL )







164 0.9 (0.7-1.1) .34
Premature birth (≤37 weeks) 2 (6.7) 5 (3.7) 164 1.9 (0.3-10.7) .48
Use of caesarean section at birth  1 (5.3) 5 (5.4) 111 1.4 (0.1-13.6) .79
Use of forceps at birth 1 (4.8) 3 (3.3) 112 1.5 (0.1-16.4) .73
Birth weight, kg 3.8 (3.3-4.0) 3.5 (3.2-4.0) 121 0.9 (0.5-1.9) .89
Weight <2.5kg at birth 0 (0.0) 4 (4.0) 121 Fisher’s 1.0
Hospital childbirth 8 (29.6) 28 (21.5) 157 1.4 (0.6-3.7) .44
Cyanosis at birth 2 (6.5) 15 (10.6) 173 0.5 (0.1-2.3) .36
Shortness of breath at birth 1 (3.1) 7 (4.9) 174 0.6 (0.1-5.0) .62
Icterus at birth 4 (12.5) 19 (13.2) 176 1.0 (0.3-3.1) .94








OR (95% CI) P
Postnatal factors
Breastfeeding 12 (75.0) 64 (72.7) 104 1.2 (0.3-4.1) .81
Duration of breastfeeding, months 6.0 (2.5-7.0) 3.0 (1.5-6.0) 68 1.3 (0.98-1.7) .07
Duration of breastfeeding  >6 months 4 (36.4) 7 (12.3) 68 5.5 (1.1-27.1) .04
History of variola vaccination 24 (77.4) 103 (72.0) 174 1.3 (0.5-3.3) .59
History of DKTP vaccination 33 (100.0) 146 (98.6) 181 Fisher’s 1.0
History of morbili vaccination 4 (15.4) 12 (10.4) 141 1.5 (0.4-5.2) .52
History of otitis 12 (37.5) 43 (29.3) 179 1.5 (0.7-3.4) .32
History of pseudo croup 2 (6.5) 15 (11.0) 167 0.5 (0.1-2.3) .37
History of surgery for acute tonsillitis 18 (52.9) 97 (63.4) 187 0.6 (0.3-1.3) .22
Age at surgery for acute tonsillitis, 
years
4 (2-5) 4 (4-5) 100 0.9 (0.6-1.2) .37
History of pneumonia 1 (3.6) 30 (23.3) 157 0.1 (0.01-0.9) .04
History of scarlet fever 3 (9.1) 11 (7.3) 183 1.2 (0.3-4.6) .81
History of morbili 28 (82.4) 127 (84.7) 184 0.9 (0.3-2.4) .82
History of rubella 12 (40.0) 72 (50.0) 174 0.7 (0.3-1.6) .37
History of varicella 23 (69.7) 110 (72.8) 184 0.9 (0.4-2.0) .73
History of smallpox 1 (3.1) 1 (0.7) 175 6.6 (0.3-125) .21
History of parotitis epidemica 20 (60.6) 86 (57.7) 182 1.0 (0.5-2.3) .90
≥1 of scarlet fever, morbili, rubella, 
varicella, smallpox, parotitis 
epidemica
32 (94.1) 147 (97.4) 185 0.5 (0.1-2.8) .41
≥1 of scarlet fever, rubella, varicella, 
smallpox, parotitis epidemica
30 (88.2) 137 (91.9) 183 0.7 (0.2-2.4) .58
Exposure
Contact with animals 7 (23.3) 43 (31.9) 165 0.7 (0.3-1.7) .42
Pets 20 (60.6) 87 (58.8) 181 1.1 (0.5-2.5) .74
Firstborn child 11 (32.4) 45 (38.4) 180 0.7 (0.3-1.6) .42
Rented house 10 (34.5) 68 (54.0) 155 0.4 (0.2-1.03) .06
Dusty or damp vs. dry house 3 (11.5) 10 (8.1) 150 1.4 (0.3-5.5) .65
Rotten floor in house 3 (9.7) 4 (3.1) 161 3.6 (0.7-17.7) .12
Mould in house 4 (12.9) 7 (5.4) 160 3.0 (0.8-11.5) .11
≥1 of dusty/damp house, rotten floor, 
mould in house
9 (33.3) 16 (13.9) 142 3.1 (1.2-8.2) .02
Old state of house 7 (24.1) 54 (40.6) 162 0.4 (0.2-1.1) .09
Kapok/feather mattress 6 (18.8) 12 (8.3) 177 2.3 (0.8-6.7) .13
Kapok/feather pillow 10 (32.3) 41 (29.3) 171 1.1 (0.5-2.6) .81
Use of gas heater 15 (53.6) 69 (52.7) 159 1.0 (0.4-2.4) .94








OR (95% CI) P
Family history
Age of father, years 40 (38-44) 40 (36-44) 161 1.0 (0.98-1.1) .19
Age father at birth of child, years 31 (28-35) 30 (27-34) 161 1.0 (0.98-1.1) .19
Age of mother, years 38 (34-40) 37 (34-42) 162 1.0 (0.95-1.1) .73
Age mother at birth of child, years 28 (24-31) 27 (25-32) 162 1.0 (0.9-1.1) .73
Father with asthma 7 (25.0) 17 (12.5) 164 2.6 (0.9-7.2) .07
Father with bronchitis 7 (25.0) 24 (18.0) 161 1.5 (0.5-4.0) .44
Father with eczema 3 (10.7) 15 (11.4) 160 1.0 (0.3-3.8) .99
Father with hayfever 1 (3.6) 13 (9.8) 161 0.5 (0.1-4.0) .50
Father with atopic symptoms (asthma, 
eczema, hay fever)
9 (32.1) 38 (27.9) 164 1.4 (0.6-3.5) .44
Mother with asthma 0 (0.0) 17 (12.6) 163 Fisher’s .046
Mother with bronchitis 3 (10.7) 25 (18.7) 162 0.6 (0.2-2.0) .37
Mother with eczema 0 (0.0) 15 (11.3) 160 Fisher’s .08
Mother with hayfever 1 (3.6) 12 (9.0) 161 0.4 (0.05-3.1) .37
Mother with atopic symptoms 
(asthma, eczema, hay fever)
1 (3.7) 39 (28.9) 162 0.1 (0.01-0.7) .02
Rest of the family with asthma 12 (41.4) 67 (48.6) 167 0.8 (0.4-1.8) .59
Rest of the family with bronchitis 12 (44.4) 69 (51.5) 161 0.8 (0.3-1.8) .54
Rest of the family with eczema 9 (34.6) 43 (32.8) 157 1.2 (0.5-3.0) .68
Rest of the family with hay fever 3 (10.7) 18 (14.0) 157 0.8 (0.2-3.1) .77
Family with atopic symptoms (asthma, 
eczema, hay fever)
19 (65.5) 91 (66.4) 166 1.1 (0.5-2.6) .83
Family members with rheumatoid 
arthritis
4 (13.3) 24 (17.6) 166 0.7 (0.2-2.1) .50
Family members with heart disease 10 (33.3) 21 (15.6) 165 2.8 (1.1-6.8) .03
Family members with mental 
retardation
0 (0.0) 8 (5.9) 165 Fisher’s .35
Family members with diabetes 
mellitus
9 (30.0) 39 (28.5) 167 1.1 (0.4-2.6) .88
Family members with leukaemia 3 (10.0) 2 (1.5) 166 7.6 (1.2-49.0) .03
















188 1.0 (0.99-1.1) .12
FEV1 % predicted < 80 16 (47.1) 102 (66.2) 188 0.5 (0.2-0.97) .04
FEV1 % predicted <70 7 (20.6) 47 (30.5) 188 0.7 (0.3-1.6) .36








FEV1%IVC < 70 10 (29.4) 52 (33.8) 188 0.8 (0.4-1.9) .70




FEF25-75%IVC < 70 13 (46.4) 57 (47.5) 148 1.0 (0.4-2.3) .99
FEF25-75%IVC < 50 4 (14.3) 24 (20.0) 148 0.7 (0.2-2.4) .62
RV%TLC 20.5 (5.9) 21.3 (6.8) 187 1.0 (0.9-1.05) .69
Skin prick test (histamine-adjusted)
House dust mite positive 11 (35.5) 66 (45.5) 176 0.7 (0.3-1.6) .44
Hairs and feathers positive 9 (29.0) 42 (29.4) 174 1.1 (0.4-2.5) .91
Moulds positive 4 (13.3) 8 (5.6) 173 3.6 (0.9-14.1) .07
Grass pollen positive 8 (25.8) 24 (16.8) 174 2.0 (0.8-5.1) .15
Any SPT positive 14 (45.2) 74 (51.4) 175 0.9 (0.4-1.9) .69
BHR provocation test
2log (Histamine threshold), mg/ml 3 (2-4) 3 (2-4) 188 1.0 (0.8-1.3) .92
Histamine threshold < 8 mg/ml 19 (55.9) 79 (51.3) 188 1.3 (0.6-2.8) .53
Histamine threshold < 4 mg/ml 10 (29.4) 42 (27.3) 188 1.1 (0.5-2.6) .75
Data are presented as mean (SD), median (25th-75th percentile), or n (%). Odds Ratios (OR) with 95% 
Confidence Intervals (CI) are given for a logistic regression model adjusted for age at visit 1 and sex. If 
one of the groups contains 0 cases the p-value for the Fisher’s exact test is given. 









OR (95% CI) P
Characteristics
Age at first visit, years 9.7 (1.5) 9.8 (1.5) 71 1.0 (0.6-1.5) .94





71 1.0 (0.9-1.1) .82
Male sex 7 (70.0) 38 (62.3) 71 1.4 (0.3-6.0) .64
Weight at first visit, kg 33.0 (5.7) 33.0 (6.5) 71 1.0 (0.9-1.2) .95
Height at first visit, cm 145.9 (10.4) 143.4 (10.3) 71 1.1 (0.96-1.2) .22
Cough 8 (80.0) 50 (82.0) 71 0.9 (0.2-4.7) .87
Age at development of cough, years 3 (1 – 5) 2 (1 – 7) 51 1.0 (0.8-1.3) .98
Cough accompanied by fever 2 (25.0) 28 (51.9) 62 0.3 (0.1-1.7) .17
Cough ≥ 3 months 3 (37.5) 26 (48.1) 62 0.6 (0.1-2.9) .54
Sputum 4 (40.0) 36 (60.0) 70 0.4 (0.1-1.7) .21
Shortness of breath at rest 2 (22.2) 23 (39.0) 68 0.4 (0.1-2.3) .33
Shortness of breath during walking 
stairs/playing




Shortness of breath during cycling 
against the wind
6 (60.0) 45 (77.6) 68 0.4 (0.1-1.8) .24
Age at development of shortness of 
breath, years
8 (0 – 11) 4 (1 – 7) 50 1.1 (0.8-1.4) .59
Attack of dyspnea at rest with 
wheezing
7 (70.0) 51 (83.6) 71 0.4 (0.1-2.0) .29








Wheeze without a cold 5 (55.6) 23 (50.0) 55 1.3 (0.3-5.9) .72




Age at development of runny/stuffed 
nose, years
6 (1 – 10) 6 (2 – 8) 40 1.0 (0.8-1.3) .94
Eczema 4 (44.4) 24 (39.3) 70 1.3 (0.3-5.3) .75




≥3 symptoms: cough, sputum, 
shortness of breath  
at rest, attack of dyspnea at rest with 
wheezing, wheeze ever




Physical signs of pulmo ronchi 3 (60.0) 25 (62.5) 45 0.7 (0.1-6.5) .79
Physical signs of thorax deformation 1 (20.0) 2 (30.0) 45 0.4 (0.04-5.3) .51
Supplemental table 4: complete list of childhood factors ComR versus PersA at visit 3










OR (95% CI) P
Peripheral blood measurements
LN Leukocyte count, cells x 106/L 9.0 (0.3) 9.0 (0.3) 69 2.3 (0.2-26.4) .52
Leukocyte count level 75th percentile 
(>9.600 x 106/L)
5 (50.0) 14 (23.7) 69 3.2 (0.8-12.6) .10
Leukocyte count level 90th percentile 
(>10.880 x 106/L )
1 (10.0) 4 (6.8) 69 1.7 (0.2-18.1) .65
Haemoglobin, g/dL 13.4 (1.2) 13.5 (1.0) 69 0.8 (0.4-1.6) .58
Haemoglobin level 75th percentile 
(>14.2g/dL)
3 (30.0) 13 (22.0) 69 1.4 (0.3-6.5) .64
Haemoglobin level 90th percentile 
(>14.8g/dL)
1 (10.0) 6 (10.2) 69 1.0 (0.1-9.4) .99
LN eosinophil count, cells x 106/L 5.8 (0.9) 5.8 (1.2) 69 1.0 (0.6-1.9) .96
Eosinophil count level 75th percentile 
(>699 x 106/L)
1 (10.0) 17 (28.8) 69 0.3 (0.03-2.5) .25
Eosinophil count level 90th percentile 
(>961 x 106/L)
1 (10.0) 7 (11.9) 69 0.9 (0.1-8.7) .92
Electrophoresis total protein, g/dL 7.1 (6.5 – 7.4) 7.3 (6.8 – 7.5) 70 0.3 (0.1-1.5) .17
Total protein level 25th percentile 
(<6.8g/dL)
3 (30.0) 12 (20.0) 70 1.8 (0.4-8.2) .46
Total protein level 10th percentile 
(<6.5g/dL)
2 (20.0) 4 (6.7) 70 3.6 (0.5-23.3) .19
Electrophoresis albumin, % of total 
protein
62.3 (6.6) 65.6 (7.5) 71 0.9 (0.9-1.02) .14
Albumin level 25th percentile (<60.2g/
dL)
4 (40.0) 13 (21.3) 71 2.8 (0.6-12.1) .17
Albumin level 10th percentile (<55.6g/
dL)
2 (20.0) 5 (8.2) 71 3.1 (0.5-20.1) .23
















66 0.8 (0.5-1.1) .20
Premature birth (≤37 weeks) 1 (11.1) 1 (1.8) 66 7.7 (0.4-138) .17
Use of caesarean section at birth 0 (0.0) 3 (8.8) 40 Fisher’s 1.0
Use of forceps at birth 0 (0.0) 0 (0.0) 37 NA NA
Birth weight, kg 3.5 (3.3-3.9) 3.5 (3.0-4.0) 47 1.1 (0.3-4.7) .88
Weight <2.5kg at birth 0 (0.0) 3 (7.7) 47 Fisher’s 1.0
Hospital childbirth 2 (28.6) 12 (22.2) 61 1.4 (0.2-8.3) .73
Cyanosis at birth 0 (0.0) 6 (10.3) 68 Fisher’s .58
Shortness of breath at birth 0 (0.0) 2 (3.5) 67 Fisher’s 1.0
Icterus at birth 1 (10.0) 7 (11.9) 69 0.9 (0.1-8.3) .89
Postnatal factors
Breastfeeding 2 (50.0) 22 (64.7) 38 0.5 (0.1-4.4) .56
Duration of breastfeeding, months
5.0  
(4.0 – 5.0)
4.0 (1.8 – 7.0) 19 1.2 (0.6-2.5) .55
Duration of breastfeeding  >6 months 0 (0.0) 5 (29.4) 19 Fisher’s 1.0




History of DKTP vaccination 10 (100) 60 (100) 70 NA NA




History of otitis 4 (44.4) 16 (26.7) 69 2.3 (0.5-10.4) .26
History of pseudo croup 0 (0.0) 5 (8.5) 67 Fisher’s 1.0
History of surgery for acute tonsillitis 7 (70.0) 38 (62.3) 71 1.4 (0.3-5.9) .67
Age at surgery for acute tonsillitis, 
years
5 (2 – 8) 4 (3 – 5) 43 1.1 (0.8-1.7) .52
History of pneumonia 1 (11.1) 10 (18.9) 62 0.5 (0.1-4.8) .57
History of scarlet fever 0 (0.0) 5 (8.3) 70 Fisher’s 1.0
History of morbili 8 (80.0) 48 (81.4) 69 1.0 (0.2-5.2) .95
History of rubella 3 (33.3) 29 (51.8) 65 0.4 (0.1-2.0) .28
History of varicella 8 (80.0) 39 (65.0) 70 2.2 (0.4-11.4) .35
History of smallpox 0 (0.0) 1 (1.8) 66 Fisher’s 1.0
History of parotitis epidemica 5 (55.6) 34 (57.6) 68 1.0 (0.2-4.3) .99
≥1 of scarlet fever, morbili, rubella, 
varicella, smallpox, parotitis 
epidemica
10 (100.0) 57 (95.0) 70 Fisher’s 1.0
≥1 of scarlet fever, rubella, varicella, 
smallpox, parotitis epidemica
9 (90.0) 53 (89.8) 69 1.1 (0.1-10.6) .94










OR (95% CI) P
Exposure
Contact with animals 4 (50.0) 17 (30.9) 63 2.3 (0.5-10.5) .28
Pets 7 (77.8) 36 (59.0) 70 2.4 (0.4-12.5) .31
Firstborn child 2 (20.0) 20 (33.3) 70 0.5 (0.1-2.7) .42
Rented house 2 (28.6) 30 (55.6) 61 0.3 (0.1-1.7) .17
Dusty or damp vs. dry house 0 (0.0) 5 (10.2) 63 Fisher’s 1.0
Rotten floor in house 1 (12.5) 4 (7.5) 66 1.9 (0.2-21.3) .59
Mould in house 1 (12.5) 3 (5.5) 63 2.6 (0.2-31.6) .45
≥1 of dusty/damp house, rotten floor, 
mould in house
2 (33.3) 9 (20.0) 51 1.7 (0.3-11.6) .57
Old state of house 4 (44.4) 19 (35.2) 63 1.6 (0.4-6.6) .55
Kapok/feather mattress 2 (20.0) 6 (10.0) 70 2.2 (0.4-12.8) .39
Kapok/feather pillow 2 (20.0) 14 (24.6) 67 0.8 (0.1-4.0) .74
Use of gas heater 4 (44.4) 32 (59.3) 63 0.6 (0.1-2.4) .45
Family history
Age of father, years 38 (36 – 45) 40 (37 – 44) 61 1.0 (0.9-1.2) .71
Age father at birth of child, years 29 (26 – 34) 30 (27 – 34) 61 1.0 (0.9-1.2) .71
Age of mother, years 37 (34 – 47) 39 (36 – 42) 61 1.0 (0.9-1.2) .64
Age mother at birth of child, years 28 (24 – 36) 28 (26 – 32) 61 1.0 (0.9-1.2) .64
Father with asthma 1 (12.5) 9 (15.5) 66 0.7 (0.1-6.9) .75
Father with bronchitis  0 (0.0) 12 (21.1) 65 Fisher’s .33
Father with eczema 1 (12.5) 8 (14.0) 65 0.8 (0.1-7.7) .87
Father with hayfever 1 (12.5) 9 (15.5) 66 0.8 (0.1-7.5) .81
Father with atopic symptoms (asthma, 
eczema, hay fever)
2 (25.0) 22 (37.9) 66 0.5 (0.1-3.0) .45
Mother with asthma 0 (0.0) 7 (11.9) 67 Fisher’s .59
Mother with bronchitis 2 (25.0) 10 (17.2) 66 1.5 (0.3-9.1) .65
Mother with eczema 0 (0.0) 5 (8.6) 66 Fisher’s 1.0
Mother with hayfever 0 (0.0) 4 (6.9) 66 Fisher’s 1.0
Mother with atopic symptoms 
(asthma, eczema, hay fever)
0 (0.0) 15 (25.4) 67 Fisher’s .18
Rest of the family with asthma 4 (50.0) 30 (50.8) 67 0.9 (0.2-4.1) .92
Rest of the family with bronchitis 2 (28.6) 32 (55.2) 65 0.3 (0.1-1.8) .21
Rest of the family with eczema 3 (42.9) 20 (35.1) 64 1.4 (0.3-6.9) .71
Rest of the family with hay fever 1 (12.5) 9 (15.8) 65 0.8 (0.1-7.4) .84









OR (95% CI) P
Family with atopic symptoms (asthma, 
eczema, hay fever)
7 (87.5) 40 (67.8) 67 3.2 (0.4-28.5) .29
Family members with rheumatoid 
arthritis
3 (33.3) 10 (17.9) 65 2.5 (0.5-11.9) .26
Family members with heart disease 2 (22.2) 7 (12.5) 65 2.0 (0.3-11.5) .45
Family members with mental 
retardation
0 (0.0) 3 (5.3) 66 Fisher’s 1.0
Family members with diabetes 
mellitus
3 (33.3) 15 (26.3) 66 1.4 (0.3-7.0) .65
Family members with leukaemia 0 (0.0) 2 (3.5) 66 Fisher’s 1.0
Lung function (Quanjer-adjusted)
FEV1 % predicted 79 (68 – 86) 77 (67 – 84) 71 1.0 (0.97-1.1) .48
FEV1 % predicted < 80 6 (60.0) 39 (63.9) 71 0.8 (0.2-3.2) .78
FEV1 % predicted <70 2 (20.0) 19 (31.1) 71 0.6 (0.1-3.0) .52
IVC % predicted 88.7 (13.5) 88.0 (12.4) 71 1.0 (0.9-1.1) .97
FEV1%IVC ratio 79 (67 – 84) 73 (67 – 78) 71 1.1 (0.97-1.2) .21
FEV1%IVC < 70 3 (30.0) 19 (31.1) 71 0.9 (0.2-4.1) .94
FEF25-75%IVC 86.7 (22.1) 72.2 (24.8) 57 1.0 (0.99-1.1) .11
FEF25-75%IVC < 70 2 (22.2) 23 (47.9) 57 0.3 (0.1-1.7) .17
FEF25-75%IVC < 50 1 (11.1) 10 (20.8) 57 0.5 (0.1-4.3) .51
RV%TLC 21.4 (9.1) 21.3 (6.1) 71 1.0 (0.9-1.1) .99
Skin prick test  
(histamine-adjusted)
House dust mite positive 7 (70.0) 24 (42.9) 66 3.3 (0.8-14.2) .11
Hairs and feathers positive 5 (50.0) 15 (27.3) 65 2.9 (0.7-11.7) .15
Moulds positive 2 (22.2) 2 (3.6) 64 9.4 (0.99-89.5) .05
Grass pollen positive 3 (30.0) 11 (20.0) 65 1.9 (0.4-8.9) .42
Any SPT positive 7 (70.0) 28 (50.0) 66 2.5 (0.6-11.0) .22
BHR provocation test
2log (Histamine threshold), mg/ml 4 (3 – 4) 4 (3 – 4) 71 1.9 (0.8-4.7) .17
Histamine threshold < 8 mg/ml 4 (40.0) 28 (45.9) 71 0.8 (0.2-3.3) .78
Histamine threshold < 4 mg/ml 0 (0.0) 15 (24.6) 71 Fisher’s .11
Data are presented as mean (SD), median (25th-75th percentile), or n (%). Odds Ratios (OR) with 95% 
Confidence Intervals (CI) are given for a logistic regression model adjusted for age at visit 1 and sex. If 
one of the groups contains 0 cases the p-value for the Fisher’s exact test is given. 










OR (95% CI) P
Characteristics
Age at first visit, years 9.7 (1.4) 9.8 (1.5) 102 1.0 (0.7-1.3) .88





102 1.0 (0.9-1.1) .70
Male sex 31 (75.6) 38 (62.3) 102 1.9 (0.8-4.5) .17
Weight at first visit, kg 34.0 (7.7) 33.0 (6.5) 102 1.0 (0.96-1.1) .41
Height at first visit, cm 144.2 (9.9) 143.4 (10.3) 102 1.0 (0.96-1.1) .57
Cough 32 (80.0) 50 (82.0) 101 0.8 (0.3-2.4) .75
Age at development of cough, years 3 (1 – 7) 2 (1 – 7) 76 1.0 (0.9-1.2) .71
Cough accompanied by fever 15 (40.5) 28 (51.9) 91 0.7 (0.3-1.6) .36
Cough ≥ 3 months 12 (35.3) 26 (48.1) 88 0.6 (0.2-1.4) .24
Sputum 14 (35.9) 36 (60.0) 99 0.4 (0.1-0.8) .02
Shortness of breath at rest 9 (24.3) 23 (39.0) 96 0.5 (0.2-1.2) .12
Shortness of breath during walking 
stairs/playing
8 (21.6) 16 (30.2) 90 0.6 (0.2-1.6) .31
Shortness of breath during cycling 
against the wind
27 (69.2) 45 (77.6) 97 0.6 (0.2-1.5) .29
Age at development of shortness of 
breath, years
4 (1 – 7) 4 (1 – 7) 71 1.0 (0.9-1.1) .85
Attack of dyspnea at rest with 
wheezing
30 (75.0) 51 (83.6) 101 0.5 (0.2-1.5) .24
Wheeze ever 35 (87.5) 52 (94.5) 95 0.4 (0.1-1.9) .26
Wheeze during a cold 24 (66.7) 23 (50.0) 82 2.0 (0.8-5.0) .13
Wheeze without a cold 14 (40.0) 23 (50.0) 81 0.6 (0.3-1.6) .32
Runny or stuffed nose 27 (67.5) 37 (63.8) 98 1.2 (0.5-2.9) .67
Age at development of runny/stuffed 
nose, years
6 (1 – 8) 6 (2 – 8) 57 1.0 (0.8-1.2) .81
Eczema 18 (47.4) 24 (39.3) 99 1.4 (0.6-3.2) .41
Urticaria 3 (8.1) 7 (12.1) 95 0.7 (0.2-2.8) .59
≥3 symptoms: cough, sputum, 
shortness of breath  
at rest, attack of dyspnea at rest with 
wheezing, wheeze ever
27 (75.0) 43 (79.6) 90 0.7 (0.3-2.1) .57
Physical signs of pulmo ronchi 13 (54.2) 25 (62.5) 64 0.7 (0.2-2.1) .52
Physical signs of thorax deformation 5 (20.8) 12 (30.0) 64 0.5 (0.1-1.8) .28
Supplemental table 5: complete list of childhood factors ComR/ClinR versus PersA at visit 3









OR (95% CI) P
Peripheral blood measurements
LN Leukocyte count, cells x 106/L 9.0 (0.3) 9.0 (0.3) 99 0.8 (0.2-3.7) .80
Leukocyte count level 75th percentile 
(>9.600 x 106/L)
14 (35.0) 14 (23.7) 99 1.7 (0.7-4.3) .22
Leukocyte count level 90th percentile 
(>10.880 x 106/L)
4 (10.0) 4 (6.8) 99 1.8 (0.4-7.9) .45
Haemoglobin, g/dL 13.6 (0.9) 13.5 (1.0) 99 1.0 (0.7-1.6) .85
Haemoglobin level 75th percentile 
(>14.2g/dL)
9 (22.5) 13 (22.0) 99 0.9 (0.3-2.4) .83
Haemoglobin level 90th percentile 
(>14.8g/dL)
3 (7.5) 6 (10.2) 99 0.7 (0.2-3.1) .66
LN eosinophil count, cells x 106/L 6.0 (0.7) 5.8 (1.2) 99 1.2 (0.8-1.9) .33
Eosinophil count level 75th percentile 
(>699 x 106/L)
8 (20.0) 17 (28.8) 99 0.7 (0.3-1.8) .41
Eosinophil count level 90th percentile 
(>961 x 106/L)
2 (5.0) 7 (11.9) 99 0.4 (0.1-2.2) .31
Electrophoresis total protein, g/dL 7.1 (6.7 – 7.4) 7.3 (6.8 – 7.5) 101 0.6 (0.3-1.2) .19
Total protein level 25th percentile 
(<6.8g/dL)
11 (26.8) 12 (20.0) 101 1.4 (0.5-3.8) .48
Total protein level 10th percentile 
(<6.5g/dL)
6 (14.6) 4 (6.7) 101 2.3 (0.6-8.9) .24
Electrophoresis albumin, % of total 
protein
63.6 (8.2) 65.6 (7.5) 102 1.0 (0.9-1.02) .17
Albumin level 25th percentile (<60.2g/dL) 10 (24.4) 13 (21.3) 102 1.3 (0.5-3.4) .58
Albumin level 10th percentile (<55.6g/dL) 6 (14.6) 5 (8.2) 102 2.2 (0.6-7.9) .24
Perinatal factors
Gestational age, weeks 40.0 (39.0-40.0) 40.0 (40.0-40.0) 96 0.8 (0.6-1.1) .11
Premature birth (≤37 weeks) 4 (10.3) 1 (1.8) 96 6.0 (0.6-56.5) .12
Use of caesarean section at birth 1 (3.8) 3 (8.8) 60 0.4 (0.04-4.6) .49
Use of forceps at birth 1 (3.7) 0 (0.0) 58 Fisher’s .47
Birth weight, kg 3.5 (3.1-4.0) 3.5 (3.0-4.0) 58 1.1 (0.5-2.2) .85
Weight <2.5kg at birth 0 (0.0) 3 (7.7) 68 Fisher’s .26
Hospital childbirth 11 (33.3) 12 (22.2) 87 1.8 (0.7-4.7) .25
Cyanosis at birth 3 (7.9) 6 (10.3) 96 0.7 (0.2-3.1) .64
Shortness of breath at birth 2 (5.0) 2 (3.5) 97 1.7 (0.2-12.9) .63
Icterus at birth 6 (15.0) 7 (11.9) 99 1.3 (0.4-4.4) .65










OR (95% CI) P
Postnatal factors
Breastfeeding 19 (79.2) 22 (64.7) 58 2.1 (0.6-7.3) .23
Duration of breastfeeding, months 5.0 (2.3 – 6.0) 4.0 (1.8 – 7.0) 33 1.0 (0.8-1.4) .74
Duration of breastfeeding  >6 months 2 (12.5) 5 (29.4) 33 0.3 (0.1-2.1) .24
History of variola vaccination 30 (83.3) 42 (70.0) 96 2.2 (0.8-6.2) .15
History of DKTP vaccination 38 (97.4) 60 (100) 99 Fisher’s .39
History of morbili vaccination 7 (23.3) 4 (8.5) 77 3.2 (0.8-12.2) .09
History of otitis 14 (35.9) 16 (26.7) 99 1.6 (0.7-4.0) .28
History of pseudo croup 4 (10.8) 5 (8.5) 96 1.3 (0.3-5.2) .73
History of surgery for acute tonsillitis 25 (61.0) 38 (62.3) 102 0.9 (0.4-2.1) .83
Age at surgery for acute tonsillitis, 
years
5 (4 – 6) 4 (3 – 5) 60 1.2 (0.9-1.5) .24
History of pneumonia 5 (13.9)  10 (18.9) 89 0.7 (0.2-2.2) .52
History of scarlet fever 3 (7.5) 5 (8.3) 100 0.8 (0.2-3.8) .83
History of morbili 34 (85.0) 48 (81.4) 99 1.3 (0.4-4.0) .60
History of rubella 13 (36.1) 29 (51.8) 92 0.5 (0.2-1.2) .14
History of varicella 31 (77.5) 39 (65.0) 100 1.9 (0.8-4.9) .16
History of smallpox 1 (2.7) 1 (1.8) 94 1.8 (0.1-32.2) .68
History of parotitis epidemica 22 (56.4) 34 (57.6) 98 1.0 (0.4-2.3) .97
≥1 of scarlet fever, morbili, rubella, 
varicella, smallpox, parotitis epidemica
39 (97.5) 57 (95.0) 100 2.2 (0.2-22.2) .51
≥1 of scarlet fever, rubella, varicella, 
smallpox, parotitis epidemica
36 (90.0) 53 (89.8) 99 1.1 (0.3-4.2) .89
Exposure
Contact with animals 12 (33.3) 17 (30.9) 91 1.2 (0.5-3.1) .67
Pets 31 (81.6) 36 (59.0) 99 3.1 (1.2-8.2) .02
Firstborn child 11 (29.7) 20 (33.3) 97 0.9 (0.3-2.1) .75
Rented house 16 (48.5) 30 (55.6) 87 0.7 (0.3-1.8) .48
Dusty or damp vs. dry house 3 (8.8) 5 (10.2) 83 0.8 (0.2-3.6) .75
Rotten floor in house 2 (5.6) 4 (7.5) 89 0.8 (0.1-4.7) .80
Mould in house 5 (13.9) 3 (5.5) 91 3.2 (0.7-15.0) .14
≥1 of dusty/damp house, rotten floor, 
mould in house
9 (27.3) 9 (20.0) 78 1.6 (0.5-4.6) .41
Old state of house 14 (38.9) 19 (35.2) 90 1.3 (0.5-3.1) .60
Kapok/feather mattress 2 (5.4) 6 (10.0) 97 0.5 (0.1-2.6) .40
Kapok/feather pillow 15 (40.5) 14 (24.6) 94 2.1 (0.8-5.2) .11
Use of gas heater 17 (48.6) 32 (59.3) 89 0.7 (0.3-1.7) .41









OR (95% CI) P
Family history
Age of father, years 39 (36 – 44) 40 (37 – 44) 88 1.0 (0.9-1.1) .62
Age father at birth of child, years 29 (26 – 35) 30 (27 – 34) 88 1.0 (0.9-1.1) .62
Age of mother, years 37 (34 – 40) 39 (36 – 42) 88 1.0 (0.9-1.1) .64
Age mother at birth of child, years 27 (24 – 30) 28 (26 – 32) 88 1.0 (0.9-1.1) .64
Father with asthma 6 (16.7) 9 (15.5) 94 1.1 (0.4-3.6) .84
Father with bronchitis 2 (5.9) 12 (21.1) 91 0.2 (0.04-0.9) .04
Father with eczema 3 (8.8) 8 (14.0) 91 0.6 (0.1-2.4) .45
Father with hayfever 3 (8.8) 9 (15.5) 92 0.6 (0.1-2.6) .51
Father with atopic symptoms (asthma, 
eczema, hay fever)
9 (25.0) 22 (37.9) 94 0.6 (0.2-1.5) .27
Mother with asthma 1 (2.9) 7 (11.9) 94 0.2 (0.03-1.9) .17
Mother with bronchitis 3 (8.8) 10 (17.2) 92 0.5 (0.1-1.9) .29
Mother with eczema 2 (5.9) 5 (8.6) 92 0.7 (0.2-3.8) .67
Mother with hayfever 0 (0.0) 4 (6.9) 92 Fisher’s .29
Mother with atopic symptoms 
(asthma, eczema, hay fever)
3 (8.6) 15 (25.4) 94 0.3 (0.1-1.1) .06
Rest of the family with asthma 23 (63.9) 30 (50.8) 95 1.8 (0.7-4.1) .20
Rest of the family with bronchitis 15 (45.5) 32 (55.2) 91 0.7 (0.3-1.6) .37
Rest of the family with eczema 11 (33.3) 20 (35.1) 90 0.9 (0.4-2.3) .85
Rest of the family with hay fever 4 (12.1) 9 (15.8) 90 0.7 (0.2-2.7) .65
Family with atopic symptoms (asthma, 
eczema, hay fever)
28 (77.8) 40 (67.8) 95 1.7 (0.7-4.6) .26
Family members with rheumatoid 
arthritis
8 (22.2) 10 (17.9) 92 1.4 (0.5-4.2) .52
Family members with heart disease 8 (22.9) 7 (12.5) 91 2.0 (0.6-6.2) .24
Family members with mental 
retardation
2 (5.9) 3 (5.3) 91 1.0 (0.2-6.4) .99
Family members with diabetes 
mellitus
11 (30.6) 15 (26.3) 93 1.4 (0.5-3.6) .55
Family members with leukaemia 2 (5.7) 2 (3.5) 92 1.2 (0.2-9.8) .84









OR (95% CI) P
Lung function (Quanjer-adjusted)




FEV1 % predicted < 80 29 (70.7) 39 (63.9) 102 1.4 (0.6-3.2) .47
FEV1 % predicted <70 12 (29.3) 19 (31.3) 102 1.0 (0.4-2.5) .95




FEV1%IVC ratio 74 (67 – 79) 73 (67 – 78) 102 1.0 (0.96-1.1) .92
FEV1%IVC < 70 15 (36.6) 19 (31.1) 102 1.3 (0.5-3.0) .57












RV%TLC 20.3 (8.0) 21.3 (6.1) 102 1.0 (0.9-1.04) .53
Skin prick test (histamine-adjusted)
House dust mite positive 16 (41.0) 24 (42.9) 95 1.0 (0.4-2.2) .91
Hairs and feathers positive 13 (33.3) 15 (27.3) 94 1.3 (0.5-3.2) .56
Moulds positive 4 (10.5) 2 (3.6) 93 3.1 (0.5-18.7) .21
Grass pollen positive 7 (17.9) 11 (20.0) 94 0.9 (0.3-2.6) .83
Any SPT positive 17 (43.6) 28 (50.0) 95 0.8 (0.3-1.8) .61
BHR provocation test
2log (Histamine threshold), mg/ml 3 (2 – 4) 4 (3 – 4) 102 0.9 (0.6-1.2) .34
Histamine threshold < 8 mg/ml 26 (63.4) 28 (45.9) 102 2.2 (0.96-5.1) .06
Histamine threshold < 4 mg/ml 13 (31.7) 15 (24.6) 102 1.5 (0.6-3.6) .39
Data are presented as mean (SD), median (25th-75th percentile), or n (%). Odds Ratios (OR) with 95% 
Confidence Intervals (CI) are given for a logistic regression model adjusted for age at visit 1 and sex.  
If one of the groups contains 0 cases the p-value for the Fisher’s exact test is given. 

